Develops an on-premises AI research platform for biotechnology and pharmaceutical companies, and seeks partners to license its biologic drug candidates.
10-K for FY2025, filed Apr 15, 2026
Plans to sell directly to biotechnology and pharmaceutical companies, contract research organizations and academic research institutions; strategic partners and channel arrangements may supplement direct sales.
10-K for FY2025, filed Apr 15, 2026
10-Q for Q2 FY2026, filed Aug 19, 2026
−$1.6MView ↗
8-K, filed Sep 10, 2026
Pursuant to the Agreement, Virotek has appointed Kala as the sole and exclusive distributor and reseller of a genetic testing and screening…View ↗
8-K, filed Aug 28, 2026
On August 27, 2026, KALA BIO, Inc. (the “Company”) received a letter (the “Staff Determination Letter”) from the Listing Qualifications…View ↗
From drug development to AI
The older report centered on developing drug candidates for rare eye diseases; the latest describes an on-premises AI platform for biotech and pharmaceutical clients, while seeking to monetize legacy biologics assets.
10-K for FY2022, filed Mar 3, 2023 10-K for FY2025, filed Apr 15, 2026OverviewView ↗
Loading...